Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

45.97 -4.20 (-8.37%)
Streaming Delayed Price Updated: 3:38 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
35 36 Next >
News headline image
3 No-Brainer Growth Stocks to Buy in 2023 ↗
These stocks all fell by double digits last year. 
Via The Motley Fool
News headline image
Why Editas Medicine's Shares Jumped This Week ↗
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool
News headline image
Is Editas Medicine Stock a Buy Now? ↗
Layoffs and a thin clinical-stage pipeline aren't very encouraging. 
Via The Motley Fool
News headline image
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later ↗
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist. 
Via InvestorPlace
News headline image
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now? ↗
Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case? 
Via InvestorPlace
News headline image
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗
 
Via Benzinga
News headline image
5 Reasons to Buy Vertex Pharmaceuticals Now ↗
Vertex shares are extending last year's gains, and that trend probably isn't over. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
Vertex is heading for a new phase of growth. 
Via The Motley Fool
Expert Ratings for CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a 
Via Benzinga
News headline image
3 Things About CRISPR Therapeutics That Smart Investors Know ↗
The gene-therapy specialist's near-term outlook is quite bullish. 
Via The Motley Fool
News headline image
7 CRISPR Stocks With the Best Long-Term Potential ↗
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
News headline image
3 Healthcare Stocks to Buy and Hold for the Next 10 Years ↗
These companies have the therapies to boost revenue for a decade. 
Via The Motley Fool
News headline image
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
News headline image
3 Gene Editing Stocks With the Best Long-Term Potential ↗
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
News headline image
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics? ↗
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies. 
Via The Motley Fool
News headline image
3 Smart Stocks to Buy if a Recession Is on the Way ↗
Their products will enjoy strong demand regardless of what happens with the economy. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Stock: Bull vs. Bear ↗
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market? 
Via The Motley Fool
News headline image
7 Biotech Stocks That Will Make You Rich in 10 Years ↗
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years ↗
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
2 Stocks Down More Than 25% to Buy Right Now ↗
These companies are set for a new era of growth. 
Via The Motley Fool
News headline image
5 Potentially Explosive Stocks to Buy in 2023 ↗
These stocks all dropped in the double digits last year. But their future prospects are brilliant. 
Via The Motley Fool
News headline image
More Likely to 5X First: CRISPR Therapeutics vs. InMode ↗
These two companies are in very different situations but could generate significant returns for investors. 
Via The Motley Fool
News headline image
2 Growth Stocks You May Regret not Buying Right Now ↗
At their beaten-down valuations, these stocks have the potential to deliver some impressive returns. 
Via The Motley Fool
News headline image
Can Cathie Wood Bounce Back in 2023? ↗
Wood sticks by her strategy, no matter what the general market does. 
Via The Motley Fool
News headline image
2 Supercharged Stocks to Buy Right Now That Could Soar in 2023 ↗
These stocks have been solid performers despite the macroeconomic uncertainties in 2022. 
Via The Motley Fool
News headline image
2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗
Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow. 
Via The Motley Fool
News headline image
2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗
These biotechnology stocks are pushing ahead with promising innovations. 
Via The Motley Fool
News headline image
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.